<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048564</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01355-48</org_study_id>
    <nct_id>NCT04048564</nct_id>
  </id_info>
  <brief_title>Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)</brief_title>
  <official_title>Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®): A Multicentre, Ambispective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte BioSciences France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre ambispective cohort study involving French patients who have started or
      are receiving for less than 6 months a treatment with ponatinib. This study aims at better
      qualifying the ponatinib benefit-risk balance in real life and in relation with CML patients'
      therapeutic history.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>For participants in chronic myeloid leukemia in chronic phase (CP-CML): Proportion of participants who achieve a complete or partial cytogenetic response after the initiation of study treatment</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Chronic myeloid leukemia (CML) response criteria as defined by the European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia (Baccarani et al. Blood 2013).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For participants in chronic myeloid leukemia in accelerated phase (AP-CML) or chronic myeloid leukemia in blast phase (BP-CML): Proportion of participants who achieve a complete hematologic response</measure>
    <time_frame>up to 48 months</time_frame>
    <description>CML response criteria as defined by the European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in CP-CML phase who achieved complete hematologic response</measure>
    <time_frame>up to 48 months</time_frame>
    <description>CML response criteria as defined by the European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in AP and BP phases who achieved major (complete + partial) cytogenetic response</measure>
    <time_frame>up to 48 months</time_frame>
    <description>CML response criteria as defined by the European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieved major molecular response and/or depth molecular response: (MR4 or MR4.5 or MR5)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>CML response criteria as defined by the European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Duration of CML response criteria as defined by the European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression to AP‐CML or BP‐CML (for those participants not in AP‐CML or BP‐CML)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Time to progression to AP-CML defined as follows: Blasts in blood or marrow 15%-29%, or blasts plus promyelocytes in blood or marrow &gt; 30%, with blasts &lt; 30%; basophils in blood ≥ 20%; persistent thrombocytopenia (&lt; 100 × 10^9/L) unrelated to therapy; clonal chromosome abnormalities in Ph1 cells (CCA/Ph1), major route, on treatment. Time to progression to BP-CML defined as follows: Blasts in blood or marrow ≥ 30%; extramedullary blast proliferation, apart from spleen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose reduction (after response) in each cohort</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Includes level of response at the time of dose reduction and maintenance of response after dose reduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Time to CML response criteria as defined by the European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of progression to accelerated phase (AP-) or blast phase (BP-) CML</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Rate of progression to AP- or BP-CML as defined in European LeukemiaNet (ELN) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Survival without any progression to AP or BP according to ELN criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Overall survival defined according to ELN criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Adverse event is any untoward medical occurrence in a patient or clinical study subject administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of discontinuation due to adverse events in each dose cohort</measure>
    <time_frame>Approximately 2 years.</time_frame>
    <description>Adverse event is any untoward medical occurrence in a patient or clinical study subject administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose reductions (prior to response) in each dose cohort</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Reduction in the dose of Iclusig.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose interruptions in each dose cohort</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Interruption of Iclusig treatment.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        70 public and private French investigative centers of hematology will be recruited.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting a CML in any phase.

          -  Having initiated for less than six months a treatment with ponatinib.

          -  The ability to understand the requirements of the study and to comply with the study
             data collection procedures.

        Exclusion Criteria:

          -  Patients previously treated with investigational ponatinib (within a clinical trial).

          -  Patients receiving an investigational agent.

          -  Patients who are pregnant and/or breastfeeding.

          -  Patients with contraindications for Ponatinib according to Summary of Products
             Characteristics.

          -  Patients with life expectancy &lt; 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali G. Turnan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paris Sud University Hospitals-Bicetre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU SUD Reunion GHSR</name>
      <address>
        <city>Saint-Pierre</city>
        <state>Reunion</state>
        <zip>97410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Amiens-Picardie- Site SUD</name>
      <address>
        <city>Amiens Cedex</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU D'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Argenteuil</name>
      <address>
        <city>Argenteuil Cedex</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier D'Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Beziers</name>
      <address>
        <city>Béziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cabinet D'hematologie De La Clinique Du Parc</name>
      <address>
        <city>Castelnau-Le-Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH William Morey</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <zip>71321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Chambery</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Estaing Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand Cedex</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH De Versailles (Andre Mignot)</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Bicetre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH De Libourne</name>
      <address>
        <city>Libourne</city>
        <zip>33505</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU De Lille - Hôpital Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Limoges</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leon Berard, Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopitaux Prives Metz Centre De Belle-Isle</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH De Metz (Hopital De Mercy - CHR Metz Thionville)</name>
      <address>
        <city>Metz</city>
        <zip>57530</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH St Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU De Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Rene Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH De Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU De Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Victor Provo</name>
      <address>
        <city>Roubaix</city>
        <zip>59056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>La Clinique Sainte-Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire Du Cancer Toulouse - Oncopo</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU De Nancy - Hôpitaux De Brabois</name>
      <address>
        <city>Vandoeuvre Lès Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>Iclusig</keyword>
  <keyword>ponatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

